Brain neuropeptides in progressive supranuclear palsy.
No significant alterations in the levels of Met-enkephalin-, Leu-enkephalin-, cholecystokinin- and substance P-like immunoreactive materials were found in 10 areas of postmortem brains from patients with progressive supranuclear palsy (PSP) when compared to controls. These results are at difference with the marked decrease in the levels of enkephalin-, cholecystokinin- and substance P-like immunoreactive materials previously reported in the basal ganglia of parkinsonian patients. Since PSP and Parkinson's disease are both characterized by a severe dopamine nigrostriatal deficit, these results suggest that the decreased brain peptide concentrations found in Parkinson's disease do not simply result from a dopaminergic neuronal loss.
D000368:Aged; D001921:Brain / Q000378:metabolism*; D002766:Cholecystokinin / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism / Q000473:pathology; D004298:Dopamine / Q000378:metabolism; D004743:Enkephalin, Leucine / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D006801:Humans; D009479:Neuropeptides / Q000378:metabolism*; D013373:Substance P / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism*
D009479:Neuropeptides; D013373:Substance P; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D002766:Cholecystokinin; D004298:Dopamine